Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × OTHER × Rare Tumour × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 397 Neoplasms 311 Colorectal Neoplasms 203 Carcinoma, Non-Small-Cell Lung 197 Lung Neoplasms 179 Prostatic Neoplasms 165 Carcinoma, Hepatocellular 141 Stomach Neoplasms 129 Pancreatic Neoplasms 101 Uterine Cervical Neoplasms 95 Rectal Neoplasms 95 Multiple Myeloma 94 Leukemia, Myeloid, Acute 90 Squamous Cell Carcinoma of Head and Neck 75 Recurrence 72 Ovarian Neoplasms 68 Neoplasm Metastasis 66 Head and Neck Neoplasms 65 Brain Neoplasms 65 Colonic Neoplasms 60 Glioblastoma 57 Esophageal Neoplasms 57 Triple Negative Breast Neoplasms 54 Precursor Cell Lymphoblastic Leukemia-Lymphoma 52 Endometrial Neoplasms 50 Motor Activity 49 Small Cell Lung Carcinoma 48 Anxiety Disorders 47 Disease 46 Glioma 45

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡